Validation of the Neogen® ELISA Gabapentin Kit for Blood and Urine

Clicks: 18
ID: 328309
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #32 of 61 articles by views in journal of analytical toxicology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The validation of a semi-quantitative method for the rapid screening of whole blood and urine specimens using the Neogen® Gabapentin kit is presented. Decision points were validated at 1,000 ng/mL for whole blood and urine. The validation design was based on ANSI/ASB 036 and internal laboratory requirements. Experiments included the evaluation of sensitivity, precision, specificity, carryover, hook effect, drift, ruggedness/robustness, interference, and an authentic case sample comparison. The experimental limit of detection (LOD) for gabapentin was determined to be at least 500 ng/mL in whole blood and urine. Excellent precision was demonstrated when the assay was evaluated using the mean of three replicates from five separate runs (n = 15) at the decision point and at concentration levels -50% and +100% of the decision point. The assay was reliably able to detect gabapentin without interference from matrix components or other substances routinely detected in authentic case samples with the exception of levamisole in urine if present at unusually high concentrations. Urine samples with 50 µg/mL or more of levamisole yielded a false positive screening result. Other case sample results were comparable to those obtained with liquid chromatography tandem high-resolution mass spectrometry or liquid chromatography tandem mass spectrometry for blood and urine, respectively. The Neogen® Gabapentin kit exhibited minimal cross-reactivity for pregabalin and demonstrated excellent precision and appropriate sensitivity in both whole blood and urine, making it an efficient and reliable method to screen for gabapentin.
Reference Key
openalex_W7212155390 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nicholas B Tiscione, Chloe E Rosenberger, Leonela Placencia, Edward X Zumaeta
Journal journal of analytical toxicology
Year 2026
DOI
10.1093/jat/bkag077
URL
https://doi.org/10.1093/jat/bkag077
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.